Sara G. Pelaz , Raquel Flores-Hernández , Tatjana Vujic , Domitille Schvartz , Andrea Álvarez-Vázquez , Yuxin Ding , Laura García-Vicente , Aitana Belloso , Rocío Talaverón , Jean-Charles Sánchez , Arantxa Tabernero
{"title":"蛋白质组学方法支持 TAT-Cx43266-283 在胶质母细胞瘤中的临床意义。","authors":"Sara G. Pelaz , Raquel Flores-Hernández , Tatjana Vujic , Domitille Schvartz , Andrea Álvarez-Vázquez , Yuxin Ding , Laura García-Vicente , Aitana Belloso , Rocío Talaverón , Jean-Charles Sánchez , Arantxa Tabernero","doi":"10.1016/j.trsl.2024.06.001","DOIUrl":null,"url":null,"abstract":"<div><p>Glioblastoma (GBM) is the most frequent and aggressive primary brain cancer. The Src inhibitor, TAT-Cx43<sub>266-283</sub>, exerts antitumor effects in in vitro and in vivo models of GBM. Because addressing the mechanism of action is essential to translate these results to a clinical setting, in this study we carried out an unbiased proteomic approach. Data-independent acquisition mass spectrometry proteomics allowed the identification of 190 proteins whose abundance was modified by TAT-Cx43<sub>266-283</sub>. Our results were consistent with the inhibition of Src as the mechanism of action of TAT-Cx43<sub>266-283</sub> and unveiled antitumor effectors, such as p120 catenin. Changes in the abundance of several proteins suggested that TAT-Cx43<sub>266-283</sub> may also impact the brain microenvironment. Importantly, the proteins whose abundance was reduced by TAT-Cx43<sub>266-283</sub> correlated with an improved GBM patient survival in clinical datasets and none of the proteins whose abundance was increased by TAT-Cx43<sub>266-283</sub> correlated with shorter survival, supporting its use in clinical trials.</p></div>","PeriodicalId":23226,"journal":{"name":"Translational Research","volume":"272 ","pages":"Pages 95-110"},"PeriodicalIF":6.4000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1931524424001154/pdfft?md5=4420ed4d791a6c241a0b541ae23d1554&pid=1-s2.0-S1931524424001154-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma\",\"authors\":\"Sara G. Pelaz , Raquel Flores-Hernández , Tatjana Vujic , Domitille Schvartz , Andrea Álvarez-Vázquez , Yuxin Ding , Laura García-Vicente , Aitana Belloso , Rocío Talaverón , Jean-Charles Sánchez , Arantxa Tabernero\",\"doi\":\"10.1016/j.trsl.2024.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Glioblastoma (GBM) is the most frequent and aggressive primary brain cancer. The Src inhibitor, TAT-Cx43<sub>266-283</sub>, exerts antitumor effects in in vitro and in vivo models of GBM. Because addressing the mechanism of action is essential to translate these results to a clinical setting, in this study we carried out an unbiased proteomic approach. Data-independent acquisition mass spectrometry proteomics allowed the identification of 190 proteins whose abundance was modified by TAT-Cx43<sub>266-283</sub>. Our results were consistent with the inhibition of Src as the mechanism of action of TAT-Cx43<sub>266-283</sub> and unveiled antitumor effectors, such as p120 catenin. Changes in the abundance of several proteins suggested that TAT-Cx43<sub>266-283</sub> may also impact the brain microenvironment. Importantly, the proteins whose abundance was reduced by TAT-Cx43<sub>266-283</sub> correlated with an improved GBM patient survival in clinical datasets and none of the proteins whose abundance was increased by TAT-Cx43<sub>266-283</sub> correlated with shorter survival, supporting its use in clinical trials.</p></div>\",\"PeriodicalId\":23226,\"journal\":{\"name\":\"Translational Research\",\"volume\":\"272 \",\"pages\":\"Pages 95-110\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1931524424001154/pdfft?md5=4420ed4d791a6c241a0b541ae23d1554&pid=1-s2.0-S1931524424001154-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1931524424001154\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931524424001154","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma
Glioblastoma (GBM) is the most frequent and aggressive primary brain cancer. The Src inhibitor, TAT-Cx43266-283, exerts antitumor effects in in vitro and in vivo models of GBM. Because addressing the mechanism of action is essential to translate these results to a clinical setting, in this study we carried out an unbiased proteomic approach. Data-independent acquisition mass spectrometry proteomics allowed the identification of 190 proteins whose abundance was modified by TAT-Cx43266-283. Our results were consistent with the inhibition of Src as the mechanism of action of TAT-Cx43266-283 and unveiled antitumor effectors, such as p120 catenin. Changes in the abundance of several proteins suggested that TAT-Cx43266-283 may also impact the brain microenvironment. Importantly, the proteins whose abundance was reduced by TAT-Cx43266-283 correlated with an improved GBM patient survival in clinical datasets and none of the proteins whose abundance was increased by TAT-Cx43266-283 correlated with shorter survival, supporting its use in clinical trials.
期刊介绍：
Translational Research (formerly The Journal of Laboratory and Clinical Medicine) delivers original investigations in the broad fields of laboratory, clinical, and public health research. Published monthly since 1915, it keeps readers up-to-date on significant biomedical research from all subspecialties of medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
